Advanced

Precision diagnostics : moving towards protein biomarker signatures of clinical utility in cancer

Borrebaeck, Carl A K LU (2017) In Nature Reviews Cancer 17(3). p.199-204
Abstract

Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical... (More)

Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Reviews Cancer
volume
17
issue
3
pages
199 - 204
publisher
Nature Publishing Group
external identifiers
  • scopus:85011036342
  • wos:000395967200008
ISSN
1474-175X
DOI
10.1038/nrc.2016.153
language
English
LU publication?
yes
id
efe57cca-74f1-4f8e-bb72-968fbc95d205
date added to LUP
2017-02-16 16:14:00
date last changed
2018-10-18 02:51:17
@article{efe57cca-74f1-4f8e-bb72-968fbc95d205,
  abstract     = {<p>Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.</p>},
  author       = {Borrebaeck, Carl A K},
  issn         = {1474-175X},
  language     = {eng},
  month        = {02},
  number       = {3},
  pages        = {199--204},
  publisher    = {Nature Publishing Group},
  series       = {Nature Reviews Cancer},
  title        = {Precision diagnostics : moving towards protein biomarker signatures of clinical utility in cancer},
  url          = {http://dx.doi.org/10.1038/nrc.2016.153},
  volume       = {17},
  year         = {2017},
}